Two-step methodology for high-yield routine radiohalogenation of peptides: 18F-labeled RGD and octreotide analogs

Journal of Nuclear Medicine

Volumn 45, Issue 5, 2004, Pages 892-902

  Poethko, Thorsten ^a   Schottelius, Margret ^a   Thumshirn, Georgette ^b   Hersel, Ulrich ^b   Herz, Michael ^a   Henriksen, Gjermund ^a   Kessler, Horst ^b   Schwaiger, Markus ^a   Wester, Hans Jürgen ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

18F; Peptides; PET; Radiohalogenation

Indexed keywords

ARGINYLGLYCYLASPARTIC ACID; BENZALDEHYDE; FLUORINE 18; FLUOROBENZENE; OCTREOTIDE; OXIME; PEPTIDE; DIAGNOSTIC AGENT; FLUORINE; HALOGEN; RADIOPHARMACEUTICAL AGENT;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHEMICAL REACTION; CHEMICAL STRUCTURE; CONTROLLED STUDY; FLUORINATION; HALOGENATION; ISOTOPE LABELING; NONHUMAN; PEPTIDE SYNTHESIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOCHEMISTRY; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SOLID PHASE SYNTHESIS; SYNTHESIS; THIN LAYER CHROMATOGRAPHY; ANIMAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; EXPERIMENTAL NEOPLASM; HUMAN; MOUSE; NUDE MOUSE; RAT; SCINTISCANNING; TISSUE DISTRIBUTION;

ANIMALS; FLUORINE RADIOISOTOPES; HALOGENS; HUMANS; ISOTOPE LABELING; MICE; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; OXIMES; PEPTIDES; RADIOPHARMACEUTICALS; RATS; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 2642527947     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Reubi JC, Waser B. Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging. 2003;30:781-793.
2. Behe M, Behr TM. Cholecystokinin-B (CCK-B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies. Biopolymers. 2002;66:399-418.
3. 111In-DTPA- octreotide for diagnosis of somatostatin receptor-expressing tumors. J Nucl Med. 2003;44:708-716.
4. 3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med. 1993;20:716-731.
5. Grewal RK, Dadparvar S, Yu JQ, et al. Efficacy of Tc-99m depreotide scintigraphy in the evaluation of solitary pulmonary nodules. Cancer J. 2002;8:400-404.
6. 3- octreotide: first results in patients with meningiomas. J Nucl Med. 2001;42:1053-1056.
7. 3-octreotide (SMT487): a phase 1 clinical study - pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid coinfusion. Eur J Nucl Med Mol Imaging. 2003;30:510-518.
8. 64Cu-TETA- octreotide as a PET imaging agent for patients with neuroendocrine tumors. J Nucl Med. 2001;42:213-221.
9. 18F-labelled, carbohydrated analogue of octreotide. Eur J Nucl Med. 2003;30:117-122.
10. Stöcklin GL. Is there a future for clinical fluorine-18 radiopharmaceuticals (excluding FDG)? Eur J Nucl Med. 1998;25:1612-1616.
11. Stöcklin G, Wester HJ. Strategies for radioligand development: peptides for tumor targeting. In: Gulyas B, Müller-Gärtner HW, eds. Positron Emission Tomography: A Critical Assessment of Recent Trends. Dordrecht, The Netherlands: Kluwer Academic; 1998:57-90.
12. Okarvi SM. Recent progress in fluorine-18 labelled peptide radiopharmaceuticals. Eur J Nucl Med. 2001;28:929-938.
13. Wester HJ, Hamacher K, Stöcklin G. A comparative study of N.C.A. fluorine-18 labeling of proteins via acylation and photochemical conjugation. Nucl Med Biol. 1996;23:365-372.
14. 18F]fluorocarboxylic acids. Appl Radiat Isot. 1994;45:715-727.
15. 18F]fluoro-benzoate and its application to the labelling of a monoclonal antibody fragment. Bioconjug Chem. 1994;5:352-356.
16. 1)-octreotide, a potential radiopharmaceutical for quantitative somatostatin receptor imaging with PET: synthesis, radiolabeling, in vitro validation and biodistribution in mice. Nucl Med Biol. 1994;21:819-825.
17. 86Y-DTPA-Octreotide. Nucl Med Biol. 1997;24:275-286.
18. 7]-alpha-MSH, an alpha-melanocyte stimulating hormone analogue. Nucl Med Biol. 1997;24:171-178.
19. 21)VIP: evaluation of biological activity and localization to breast cancer tumors. Peptides. 1998;19:585-592.
20. 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res. 2001;61:1781-1785.
21. 18F-labeled human C-peptide: evaluation in monkeys using positron emission tomography. Life Sci. 2002;71:1361-1370.
22. 18F-labelled neurotensin (8-13) analogs. Nucl Med Biol. 2002;29:61-72.
23. 18F]-N-succinimidyl 4-(fluoromethyl)benzoate for protein labeling. Appl Radiat Isot. 1994;45:1155-1163.
24. 18F]-labeled benzylfluoride derivatives. Nucl Med Biol. 2000;27:163-168.
25. Keinanen TA, Hyvonen T, Khomutov AR, et al. Application of oxime formation in a radiometric assay of aminooxy compounds. Anal Biochem. 1993;208:35-43.
26. Kurth M, Pelegrin A, Rose K, et al. Site-specific conjugation of a radioiodinated phenethylamine derivative to a monoclonal antibody results in increased radioactivity localization in tumor. J Med Chem. 1993;36:1255-1261.
27. Thumshirn G, Hersel U, Goodman SL, Kessler H. Multimeric cyclic RGD peptides as potential tools for tumor targeting: solid-phase peptide synthesis and chemo-selective oxime ligation. Chem Eur J. 2003;9:2717-2125.
28. Renaudet O, Dumy P. Chemoselectively template-assembled glycoconjugates as mimics for multivalent presentation of carbohydrates. Org Lett. 2003;5:243-246.
29. Dey S, Sheppard TL. Ketone-DNA: a versatile postsynthetic DNA decoration platform. Org Lett. 2001;3:3983-3986.
30. Hamma T, Miller PS. 4-(2-Aminooxyethoxy)-2-(ethylureido)quinoline- oligonucleotide oonjugates: synthesis, binding interactions, and derivatization with peptides. Bioconjug Chem. 2003;14:320-330.
31. Zatsepin TS, Stetsenko DA, Arzumanov AA, Romanova EA, Gait MJ, Oretskaya TS. Synthesis of peptide-oligonucleotide conjugates with single and mutiple peptides attached to 2[prime]-aldehydes through thiazolidine, oxime, and hydrazine linkages. Bioconjug Chem. 2002;13:822-830.
32. Buré C, Lelièvre D, Delmas A. Identification of by-products from an orthogonal peptide ligation by oxime bonds using mass spectrometry and tandem mass spectrometry. Rapid Commun Mass Spectrom. 2000;14:2158-2164.
33. Peuralahti J, Puukka K, Hakala H, et al. Synthesis of nonluminescent lanthanide( III) chelates tethered to an aminooxy group and their applicability to biomolecule derivatization. Bioconjug Chem. 2002;13:876-880.
34. 18Fluorobenzylidene)aminooxy] butyl}-maleimide, and its application to the labelling of an oligodeoxynucleotide [abstract]. J Nucl Med. 2001;42(suppl.):256P.
35. 18F]fluorobenzylhalides. Appl Radiat Isot. 2000;52:87-92.
36. 18F-labelled tracer suitable for routine clinical imaging of sst-receptor expressing tumors using positron emission tomography. Clin Cancer Res. 2004. In press.
37. 18F]GBR-13119. J Labelled Compds Radiopharm. 1989;27:823-833.
38. Cheresh DA, Spiro RC. Biosynthetic and functional properties of an Arg-Gly-Asp-directed receptor involved in human melanoma cell attachment to vitronectin, fibrino-gen and von Willebrand factor. J Biol Chem. 1987;262:17703-17711.
39. 18F]labeled benzamides: high affinity sigma receptor ligands for PET imaging. Nucl Med Biol. 1997;24:333-340.
40. 3-octreotide by conjugation with carbohydrates. Bioconjug Chem. 2002;13:1021-1030.